JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target lifted by JPMorgan Chase & Co. from $200.00 to $209.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the specialty pharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the company. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC upped their price target on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, HC Wainwright reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $182.47.

Jazz Pharmaceuticals Trading Up 0.2 %

JAZZ opened at $143.53 on Wednesday. The stock has a market capitalization of $8.68 billion, a P/E ratio of 20.22, a P/E/G ratio of 1.04 and a beta of 0.56. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $148.06. The firm’s fifty day simple moving average is $126.28 and its 200 day simple moving average is $118.79.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. The trade was a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 5,053 shares of company stock worth $617,442. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds have recently modified their holdings of JAZZ. IFP Advisors Inc bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $25,000. Quadrant Capital Group LLC increased its stake in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP lifted its holdings in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $28,000. Finally, Allianz SE acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.